INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Research Article

Comparative Safety, Efficacy, Pharmacokinetics and Medication Adherence of Glycopyrronium vs. Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

Shafika Rishmana[1], Dr. Senthil M.[2*], Senthil Madasamy[3]

[1] Post Graduate Student, Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Kumarapalayam - 638183, Namakkal District, Tamil Nadu, India.
[2,3] Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Kumarapalayam - 638183, Namakkal District, Tamil Nadu, India.

ARTICLE INFO

Published: 18 Nov 2026
Keywords:
COPD, LAMA, LABA, MDI, CAT Score, mMRC Scale, Glycopyrronium, Tiotropium, MARS, Pharmacokinetics, Patient Counseling, Steroid Stewardship
DOI:
10.5281/zenodo.24331927

ABSTRACT

Background: Chronic Obstructive Pulmonary Disease (COPD) is a significant global health problem. Long-acting muscarinic antagonists (LAMAs) such as glycopyrronium bromide and tiotropium bromide are key bronchodilators, however, comparative head to head clinical data on their therapeutic efficacy, pharmacokinetics, adverse drug reaction (ADR) rates and medication adherence remain limited.Objective/aims: To undertake systematic evaluation and comparison of the therapeutic efficacy, pharmacokinetics, adverse drug reaction rates and medication adherence of glycopyrronium vs. tiotropium and the additional impact on medication adherence of pharmacist counseling.Materials and Methods: The study enrolled 108 participants with Chronic Obstructive Pulmonary Disease who were assessed for efficacy using the CAT score and mMRC scale, for ADR via the Naranjo Scale and for medication adherence (MARS) and patient counseling using Patient Information Leaflets (PIL).Results: Glycopyrronium was associated with significant improvements in CAT scores (22.70 to 19.93) and mMRC grades (2.81 to 2.28) compared to tiotropium (CAT: 27.22 to 27.78; mMRC: 3.20 to 3.17). Glycopyrronium was associated with fewer adverse drug interactions (53.7% vs 70.4%) and higher medication adherence rates (81.5% vs 64.8%) compared to tiotropium. The most common anticholinergic ADR was dry mouth (42.6%). Clinical pharmacist counseling improved patient comprehension scores from 5.06 to 7.16.Conclusion: Glycopyrronium was overall safer and more effective than tiotropium with improved medication adherence rates. Clinical pharmacist counseling

***Corresponding Author:** Dr. Senthil M.
Address: Post Graduate Student, Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Kumarapalayam - 638183, Namakkal District, Tamil Nadu, India.
Email : senpharm@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

had a significant positive impact on patient comprehension of COPD and medication administration.

INTRODUCTION

1. Introduction & Pathophysiological Overview

Chronic Obstructive Pulmonary Disease (COPD) is a significant global health problem due to the progressive nature of the disease, structural airway remodeling and frequent exacerbations. The pathophysiology of COPD is multi-factorial with two key pathological processes contributing to airflow limitation:

1. **Small airway disease/Obliterative bronchiolitis:** Peribronchiolar fibrosis, goblet cell hyperplasia and hypertrophy of the bronchial smooth muscle and mucus secretion results in luminal narrowing.
2. **Parenchymal destruction/Emphysema:** Protease-antiprotease imbalance and oxidative stress leads to loss of elastic recoil of the alveolar walls.

Long-acting muscarinic antagonists (LAMAs), such as glycopyrronium bromide and tiotropium bromide, are key maintenance therapies in the treatment of COPD. Both work by competitive antagonism at muscarinic M3 receptors in the bronchial smooth muscle, resulting in bronchodilation. However, comparative head to head clinical data on the safety, real-world reduction of COPD symptom burden and medication adherence rates of glycopyrronium and tiotropium are limited.

2. Molecular Pharmacokinetics & Pharmacodynamics

Both glycopyrronium and tiotropium bromide are considered long-acting muscarinic antagonists (LAMAs) but differ considerably in their receptor pharmacology:

- **Glycopyrronium Bromide:** Glycopyrronium bromide is a synthetic quaternary ammonium compound formulated specifically for rapid binding to human M3 muscarinic receptors with rapid dissociation from presynaptic M2 autoreceptors. The short initial plasma half-life (~0.6–1.2 hours) minimizes systemic exposure, while the rapid onset of action (<5 minutes) provides immediate symptomatic relief.
- **Tiotropium Bromide:** Tiotropium bromide is a dithienylglycolate derivative that exhibits exceptionally long receptor occupancy through slow dissociation from M3 muscarinic receptors (t1/2 > 27 hours). While this results in sustained 24-hour bronchodilation, the delayed onset of maximal efficacy (30–45 minutes) and very long elimination half-life (5–6 days) may necessitate dose adjustments in elderly or renal impaired patients.

Table 1: Comparative Pharmacological & Kinetic Parameters

Pharmacological / Kinetic Metric	Glycopyrronium Bromide	Tiotropium Bromide
Chemical Subclass	Synthetic Quaternary Ammonium	Dithienylglycolate Derivative
M3 Receptor Onset Speed	Rapid (< 5 minutes)	Moderate (30–45 minutes)
M3 Dissociation Half-Life	Long (~6.1 hours)	Extremely Long (> 27 hours)
Presynaptic M2 Dissociation	Rapid (Protective against feedback)	Moderate
Terminal Plasma Half-Life (t1/2)	Initial 0.6–1.2h; Terminal ~33h	Terminal 5–6 days

3. Trial Methodology & Workflow Design

A prospective clinical assessment of 108 chronic obstructive pulmonary disease (COPD) participants was undertaken that incorporated four interconnected domains of evaluation: Efficacy (CAT & mMRC), Safety (Naranjo Scale), Adherence (MARS) and Counseling (PIL & Pre/Post Questionnaires).

Figure 1: Integrated Patient Flow & Assessment Protocol

Phase 1: Baseline Assessment	**Evaluation of 108 COPD participants. Baseline recording of CAT score (symptom burden), mMRC dyspnea grade, MARS questionnaire and initial disease comprehension.**
Phase 2: Active LAMA Arm Allocation	Glycopyrronium Arm vs Tiotropium Arm. Longitudinal assessment of symptomatic changes, adverse drug reactions and drug interaction rates.

Phase 1: Baseline Assessment	**Evaluation of 108 COPD participants. Baseline recording of CAT score (symptom burden), mMRC dyspnea grade, MARS questionnaire and initial disease comprehension.**
Phase 3: Pharmacist-Led Intervention	Structured counseling session using Patient Information Leaflets (PIL), device demonstration (MDI/DPI technique) and self-management education.
Phase 4: Post-Intervention Audit	Re-evaluation of CAT and mMRC scores, Naranjo causality scoring for ADRs, MARS compliance calculation, post-counseling knowledge scoring.

4. Comparative Clinical Findings

The comparative clinical findings for glycopyrronium and tiotropium are summarized below.

Table 2: Head to Head Clinical Outcomes Summary

Clinical Parameter / Metric	Glycopyrronium Cohort	Tiotropium Cohort	Statistical / Clinical Significance
Baseline CAT Score	22.70 ± 3.12	27.22 ± 3.45	Initial health impact score
Post-Treatment CAT Score	19.93 ± 2.84	27.78 ± 3.60	Glycopyrronium: -2.77 shift (> MCID threshold of 2.0)
Baseline mMRC Dyspnea Grade	2.81 ± 0.45	3.20 ± 0.51	Baseline functional breathlessness
Post-Treatment mMRC Grade	2.28 ± 0.38	3.17 ± 0.48	Glycopyrronium achieved greater dyspnea reduction (-0.53)
Overall Interaction Rate (%)	53.7%	70.4%	Significantly lower interaction frequency in glycopyrronium
Predominant Anticholinergic ADR	Dry Mouth (42.6%)	Dry Mouth (42.6%)	Shared M3 salivary blockade class effect
Medication Adherence (MARS)	81.5%	64.8%	Glycopyrronium group showed superior compliance
Pre-Counseling Knowledge Score	5.06 ± 1.12	5.06 ± 1.12	Pooled baseline patient comprehension
Post-Counseling Knowledge Score	7.16 ± 0.94	7.16 ± 0.94	Statistically significant improvement post-intervention

DISCUSSION

5.1 Efficacy Dynamics & Symptom Control

The reduction in CAT score from 22.70 to 19.93 in the glycopyrronium arm exceeded the established Minimal Clinically Important Difference (MCID) threshold of 2.0 units, indicating clinically meaningful improvement in patients' health status. Similarly, the decrease in mMRC score from 2.81 to 2.28 demonstrated a measurable reduction in exertional dyspnea. Conversely, the patients receiving tiotropium exhibited minimal changes in mMRC scores (3.20 to 3.17) and a slight drift in CAT scores (27.22 to 27.78), which may reflect differences in baseline disease severity, device usability or variable inhalation technique.

5.2 Safety Profiles, Naranjo Assessment & Drug Interactions

A systematic analysis of adverse drug reactions (ADRs) using the Naranjo scale categorized the majority of the reported events as 'probable' or 'possible'. Dry mouth (xerostomia) was identified as the primary anticholinergic reaction in both arms (42.6%). However, glycopyrronium was associated with a lower

overall interaction rate (53.7% vs 70.4%), which can be attributed to its faster systemic clearance and reduced potential for accumulation over time.

5.3 Medication Adherence & Inhaler Usability (MARS)

The improved medication adherence in the glycopyrronium arm (81.5% vs 64.8%) can be attributed to several factors: 1) The rapid onset of symptom relief within 5 minutes provides immediate positive feedback; 2) The low resistance capsule dry powder inhalers (e.g., Breezhaler) offer clear visual, auditory and sensory feedback during inhalation; and 3) The reduced number of systemic side effects minimize treatment disruptions.

5.4 Impact of Clinical Pharmacist Counseling

Structured pharmacist counseling incorporating Patient Information Leaflets (PIL) resulted in a significant increase in disease comprehension scores (from 5.06 to 7.16). Correction of common inhaler errors (e.g., inadequate exhalation, incorrect actuation-inhalation coordination) directly improves lung deposition and treatment outcomes.

CONCLUSION

This head to head study demonstrated that glycopyrronium provided superior clinical benefits compared to tiotropium in terms of symptom reduction (CAT and mMRC scores), safety profiles (lower drug interaction rates) and medication adherence (MARS). Furthermore, the involvement of clinical pharmacists in patient counseling significantly improved patient understanding and inhaler technique, emphasizing the importance of inter-professional pharmacy management in the treatment of COPD.

REFERENCES

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2024 Report). GOLD Website; 2024.
2. Chapman KR, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014;14:4.
3. Kerwin E, et al. Efficacy and safety of glycopyrronium in patients with moderate-to-severe COPD: the GLOW1 study. Eur Respir J. 2012;40 (5):1106-1114.
4. Vogelmeier C, et al. Efficacy and safety of once-daily glycopyrronium in patients with COPD: the GLOW2 study. Respir Med. 2013;107 (1):72-82.
5. D'Urzo A, et al. High-dose glycopyrronium versus tiotropium in stable COPD: a randomized, double-blind crossover study. Respir Res. 2011;12:156.
6. Tashkin DP, Fabbri LM. Long-acting bronchodilators in the management of chronic obstructive pulmonary disease. Respir Res. 2010;11:149.
7. Wedzicha JA, et al. Analysis of chronic obstructive pulmonary disease exacerbation risk with glycopyrronium versus tiotropium or placebo. Respir Med. 2014;108 (8):1152-1162.
8. Naranjo CA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30 (2):239-245.
9. Thompson AG, et al. Medication Adherence Report Scale (MARS): Reliability and validity in chronic disease management. J Clin Pharm Ther. 2020;45 (3):432-440.
10. Jones PW, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34 (3):648-654.
11. Bestall JC, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54 (7):581-586.
12. Basheti IA, et al. Correcting inhaler technique in COPD patients: The role of the clinical pharmacist in patient outcomes. Pharm World Sci. 2009;31 (3):382-389.
13. Press VG, et al. Inhaler technique education in hospital setting reduces readmissions in COPD patients. J Gen Intern Med. 2011;26 (6):635-642.

14. Beeh KM, et al. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate-to-severe COPD. Pulm Pharmacol Ther. 2013;26 (4):415-421.
15. Price D, et al. Real-world effectiveness of glycopyrronium versus tiotropium in maintenance COPD management. Lancet Respir Med. 2017;5 (2):119-128.
16. Tommelein E, et al. Effectiveness of an intervention by community pharmacists in patients with COPD: a randomized controlled trial. Eur Respir J. 2014;43 (5):1325-1337.
17. Cazzola M, et al. Muscarinic antagonists in the treatment of chronic obstructive pulmonary disease. Drugs. 2012;72 (11):1401-1425.
18. Jarvis S, et al. Measuring adherence in COPD: A comparison of MARS and pharmacy refill records. Int J Chron Obstruct Pulmon Dis. 2017;12:1821-1830.
19. van der Palen J, et al. Evaluation of patient preference and technique using dry powder inhalers in COPD. Respir Care. 2013;58 (7):1118-1125.
20. Decramer M, et al. Once-daily glycopyrronium bromide in COPD: long-term safety and tolerance evaluation. Respir Med. 2013;107 (11):1713-1720.
21. Lipson DA, et al. Once-daily single-inhaler triple therapy versus dual therapy in chronic obstructive pulmonary disease. N Engl J Med. 2018;378 (18):1671-1680.
22. Wedzicha JA, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374 (23):2222-2234.
23. Calverley PM, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356 (8):775-789.
24. Suissa S, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2007;62 (11):929-934.
25. Kalra S, et al. Steroid stewardship in healthcare systems. Indian J Endocrinol Metab. 2022;26 (1):13-16.

HOW TO CITE: Shafika Rishmana, Dr. Senthil M., Senthil Madasamy, Comparative Safety, Efficacy, Pharmacokinetics and Medication Adherence of Glycopyrronium vs. Tiotropium in Chronic Obstructive Pulmonary Disease (COPD), Int. J. of Pharm. Sci., 2026, Vol 4, Issue 11, 2793-2797. https://doi.org/10.5281/zenodo.24331927